BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Algynomics And Orthogen AG Establish An Alliance In Individualized Orthopedic Medicine


2/5/2007 11:24:35 AM

CHAPEL HILL, North Carolina and DUSSELDORF, Germany, February 5 /PRNewswire/ -- Algynomics and Orthogen announced a Strategic Alliance in the area of Individualized Orthopedic Medicine. The alliance will facilitate clinical studies designed to identify genetic markers of orthopedic diseases and responses to pharmacological and non-pharmacological treatments. "New discoveries in the area of pain genetics will soon change clinical practice by helping treating healthcare providers to choose the best treatment options for their orthopedic patients", said Dr. William Maixner, President of Algynomics. Algynomics' Chief Scientific Officer, Dr. Luda Diatchenko, has published several findings in the area of pain genetics, including a recent article in Science (December 2006), which has identified a unique genetic basis to common musculoskeletal pain conditions.

Chronic musculoskeletal pain conditions such as osteoarthritis, fibromyalgia syndrome, temporomandibular joint disorders and degenerative spine disease are leading causes of adult disability, affecting 15-30% of the North American and European populations. The susceptibility to develop these conditions and the responses to treatment is highly variable and influenced by variations in several genes.

A current joint ongoing prospective randomized study in knee-OA is underway. This study will identify genetic polymorphisms that predict the treatment responses to interarticular hyaluronic acid (HA) or Orthokine, a product of Orthogen proven to be effective and safe for the treatment of OA and sciatica. The results will be presented at the AAOS in San Diego (February, 15). "In the future, gene tests could help orthopedic surgeons to decide if a disc prolapse is better treated by surgery or with agents such as Orthokine", said Dr. Peter Wehling, President of Orthogen.

Press Contact: Algynomics, Inc. Dr. William Maixner 125 Ironwoods Drive Chapel Hill, NC 27516 Tel.: +1-919-672-4542 E-mail: wmaixner@algynomics.comwww.algynomics.com Orthogen AG Antje Kassel E-mail: antje.kassel@orthogen.comwww.orthogen.com

Orthogen AG

CONTACT: Press Contact: Algynomics, Inc., Dr. William Maixner, 125Ironwoods Drive, Chapel Hill, NC 27516, Tel.: +1-919-672-4542, E-mail:wmaixner@algynomics.com, www.algynomics.com; Orthogen AG, Antje Kassel,E-mail: antje.kassel@orthogen.com, www.orthogen.com



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES